Bacteremia due to Rothia mucilaginosa after chemotherapy for myeloid malignancies

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The number of reported cases of bacteremia due to Rothia mucilaginosa (R. mucilaginosa), a component of the normal flora of human gastrointestinal tract mucosa, is limited. We encountered three cases of bacteremia due to R. mucilaginosa during neutropenia after chemotherapy for myeloid malignancies. Although all three patients were successfully treated with antimicrobial agents, one patient developed disseminated lesions in the lungs and soft tissue. The portal of R. mucilaginosa bacteremia is reportedly mucositis or dental disorders; however, no such complications were identified in our patients. Even in the absence of a preexisting portal, R. mucilaginosa should be recognized as a potential causative pathogen of bacteremia during neutropenic periods. Accumulations of cases and isolates are required to further elucidate the risk factors for developing R. mucilaginosa bacteremia, its clinical course, and the optimal antimicrobial treatment.

Original languageEnglish
Pages (from-to)687-691
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume56
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

Bacteremia
Drug Therapy
Neoplasms
Mucositis
Anti-Infective Agents
Neutropenia
Gastrointestinal Tract
Tooth
Mucous Membrane
Lung
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{3e0102d0aec646a89d47f556946896c7,
title = "Bacteremia due to Rothia mucilaginosa after chemotherapy for myeloid malignancies",
abstract = "The number of reported cases of bacteremia due to Rothia mucilaginosa (R. mucilaginosa), a component of the normal flora of human gastrointestinal tract mucosa, is limited. We encountered three cases of bacteremia due to R. mucilaginosa during neutropenia after chemotherapy for myeloid malignancies. Although all three patients were successfully treated with antimicrobial agents, one patient developed disseminated lesions in the lungs and soft tissue. The portal of R. mucilaginosa bacteremia is reportedly mucositis or dental disorders; however, no such complications were identified in our patients. Even in the absence of a preexisting portal, R. mucilaginosa should be recognized as a potential causative pathogen of bacteremia during neutropenic periods. Accumulations of cases and isolates are required to further elucidate the risk factors for developing R. mucilaginosa bacteremia, its clinical course, and the optimal antimicrobial treatment.",
author = "Sumiko Kohashi and Takehiko Mori and Yuya Koda and Taku Kikuchi and Jun Kato and Takayuki Shimizu and Kayoko Sugita and Naoki Hasegawa and Mitsuru Murata and Shinichiro Okamoto",
year = "2015",
month = "6",
day = "1",
doi = "10.11406/rinketsu.56.687",
language = "English",
volume = "56",
pages = "687--691",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "6",

}

TY - JOUR

T1 - Bacteremia due to Rothia mucilaginosa after chemotherapy for myeloid malignancies

AU - Kohashi, Sumiko

AU - Mori, Takehiko

AU - Koda, Yuya

AU - Kikuchi, Taku

AU - Kato, Jun

AU - Shimizu, Takayuki

AU - Sugita, Kayoko

AU - Hasegawa, Naoki

AU - Murata, Mitsuru

AU - Okamoto, Shinichiro

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The number of reported cases of bacteremia due to Rothia mucilaginosa (R. mucilaginosa), a component of the normal flora of human gastrointestinal tract mucosa, is limited. We encountered three cases of bacteremia due to R. mucilaginosa during neutropenia after chemotherapy for myeloid malignancies. Although all three patients were successfully treated with antimicrobial agents, one patient developed disseminated lesions in the lungs and soft tissue. The portal of R. mucilaginosa bacteremia is reportedly mucositis or dental disorders; however, no such complications were identified in our patients. Even in the absence of a preexisting portal, R. mucilaginosa should be recognized as a potential causative pathogen of bacteremia during neutropenic periods. Accumulations of cases and isolates are required to further elucidate the risk factors for developing R. mucilaginosa bacteremia, its clinical course, and the optimal antimicrobial treatment.

AB - The number of reported cases of bacteremia due to Rothia mucilaginosa (R. mucilaginosa), a component of the normal flora of human gastrointestinal tract mucosa, is limited. We encountered three cases of bacteremia due to R. mucilaginosa during neutropenia after chemotherapy for myeloid malignancies. Although all three patients were successfully treated with antimicrobial agents, one patient developed disseminated lesions in the lungs and soft tissue. The portal of R. mucilaginosa bacteremia is reportedly mucositis or dental disorders; however, no such complications were identified in our patients. Even in the absence of a preexisting portal, R. mucilaginosa should be recognized as a potential causative pathogen of bacteremia during neutropenic periods. Accumulations of cases and isolates are required to further elucidate the risk factors for developing R. mucilaginosa bacteremia, its clinical course, and the optimal antimicrobial treatment.

UR - http://www.scopus.com/inward/record.url?scp=84946107138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946107138&partnerID=8YFLogxK

U2 - 10.11406/rinketsu.56.687

DO - 10.11406/rinketsu.56.687

M3 - Article

VL - 56

SP - 687

EP - 691

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 6

ER -